



Teva Pharmaceutical Industries Ltd.

Executives

Prof. Yitzhak Peterburg
Chairman of the Board

Erez Vigodman
President and Chief
Executive Officer

Eyal Desheh
Group Executive Vice
President, Chief Financial
Officer

Senior Executives

Iris Beck-Codner
Group Executive Vice
President, Corporate
Marketing Excellence and
Communication

Richard S. Egosi
Group Executive Vice
President & Chief Legal
Officer & Company
Secretary

Dr. Michael Hayden
President Global R&D &
Chief Scientific Officer

Dr. Robert Koremans
President & CEO, Global
Specialty Medicines

Dr. Carlo de Notaristefani
President and CEO Global
Operations

Sigurdur (Siggj) Olafsson
President & CEO, Global
Generic Medicines

Mark Sabag
Group Executive Vice
President, Human
Resources

Founded in Israel in 1901 by three young pharmacists, Teva Pharmaceutical Industries Limited is a leading global pharmaceutical company. Teva is committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. As the world's largest generics drug company with a strong specialty medicines portfolio, Teva is strategically positioned to contribute to and benefit from fast-moving changes in the global healthcare environment. Teva has a direct presence in approximately 60 countries and currently employs approximately 45,000 people around the world.



Teva's generics business is ranked number one in 30 of the 62 markets in which it operates. The company is the largest generic drug company in the United States, where it markets approximately 375 generic products in more than 1,100 dosage strengths and packaging sizes, including oral, injectables and inhaled products. It is also the largest generic pharmaceuticals company in the European Union.

Teva has the largest generic pharmaceuticals research & development team in the industry, allowing the company to generate a robust pipeline of generic medicines in a range of effective dosage forms, and quickly bring those medicines to patients. Additionally, Teva has a remarkable



Teva's business strategy is focused on addressing the growing global need for medicines, and evolving market, economic and legislative dynamics. These dynamics include the aging population, increased spending on pharmaceuticals in emerging markets, economic pressure on governments and private payors to provide accessible healthcare solutions, legislative and regulatory reforms, unmet patient needs, an increase in patient awareness and the growing importance of over-the-counter (OTC) medicines.

Generic Medicines

As the world's leading generic drug maker, Teva touches the lives of millions of patients every day and billions of patients every year through the size and scale of its global product portfolio, which boasts more than 1,000 molecules. The company's generics products cover almost every major therapeutic area, including cardiovascular, Central Nervous System (CNS), oncology, and diabetes.

track record in new market development and high-quality manufacturing on a global scale.

Specialty Medicines

Teva maintains a world-leading position in specialty pharmaceutical solutions in Central Nervous System disorders (including multiple sclerosis, neurodegenerative diseases and pain) and Respiratory illness (including asthma and chronic obstructive pulmonary disease), both areas underpinned by significant and growing unmet patient needs. Through cutting-edge R&D, Teva is focused on continuing to build an innovative and focused pipeline in these core therapeutic areas. Teva also has significant product portfolios in women's health and oncology.

CNS: Teva's innovative CNS portfolio includes three leading proprietary drugs: Copaxone®, Teva's leading branded product for the treatment of relapsing-remitting multiple sclerosis, which